mTOR Inhibitor Treatments, Response, Duration of Fasting, and Clinical Adverse Events
| Patients . | mTOR Inhibitor . | Age at Start, mo . | Maximal Dosage, mg/m2 · d . | Trough Level, μg/L (Mean) . | Duration of Treatment, mo . |
|---|---|---|---|---|---|
| 1 | Sirolimus | 28 | 2.1 | 3.1–11.4 (6.6) | 4 |
| 2 | Sirolimus | 40 | 5.9 | 3–11.8 (6.7) | 16; continuing treatment |
| 3 | Sirolimus | 27 | 3.7 | 4.4–23.5 (11.9) | 6 |
| 4 | Sirolimus | 7 | 3.2 | 4.4–4.8 (4.6) | 5 |
| 5 | Sirolimus | 57 | 3.5 | 1.6–10 (6.8) | 15; continuing treatment |
| 6 | Everolimus | 24 | 9.8 | 2.2–28.7 (9.9) | 7 |
| 7 | Sirolimus | 14 | 1 | 9.1–11.5 (10.3) | 1 |
| 8 | Sirolimus | 1 | 2.3 | 3.2–16.5 (8.9) | 3 |
| 9 | Sirolimus | 1 | 1.4 | 7–19 (14.1) | 4; continuing treatment |
| 10 | Sirolimus | 1 | 1.2 | 8.7–15.3 (11.2) | 1 |
| Patients . | mTOR Inhibitor . | Age at Start, mo . | Maximal Dosage, mg/m2 · d . | Trough Level, μg/L (Mean) . | Duration of Treatment, mo . |
|---|---|---|---|---|---|
| 1 | Sirolimus | 28 | 2.1 | 3.1–11.4 (6.6) | 4 |
| 2 | Sirolimus | 40 | 5.9 | 3–11.8 (6.7) | 16; continuing treatment |
| 3 | Sirolimus | 27 | 3.7 | 4.4–23.5 (11.9) | 6 |
| 4 | Sirolimus | 7 | 3.2 | 4.4–4.8 (4.6) | 5 |
| 5 | Sirolimus | 57 | 3.5 | 1.6–10 (6.8) | 15; continuing treatment |
| 6 | Everolimus | 24 | 9.8 | 2.2–28.7 (9.9) | 7 |
| 7 | Sirolimus | 14 | 1 | 9.1–11.5 (10.3) | 1 |
| 8 | Sirolimus | 1 | 2.3 | 3.2–16.5 (8.9) | 3 |
| 9 | Sirolimus | 1 | 1.4 | 7–19 (14.1) | 4; continuing treatment |
| 10 | Sirolimus | 1 | 1.2 | 8.7–15.3 (11.2) | 1 |
mTOR Inhibitor Treatments, Response, Duration of Fasting, and Clinical Adverse Events
| Patients . | mTOR Inhibitor . | Age at Start, mo . | Maximal Dosage, mg/m2 · d . | Trough Level, μg/L (Mean) . | Duration of Treatment, mo . |
|---|---|---|---|---|---|
| 1 | Sirolimus | 28 | 2.1 | 3.1–11.4 (6.6) | 4 |
| 2 | Sirolimus | 40 | 5.9 | 3–11.8 (6.7) | 16; continuing treatment |
| 3 | Sirolimus | 27 | 3.7 | 4.4–23.5 (11.9) | 6 |
| 4 | Sirolimus | 7 | 3.2 | 4.4–4.8 (4.6) | 5 |
| 5 | Sirolimus | 57 | 3.5 | 1.6–10 (6.8) | 15; continuing treatment |
| 6 | Everolimus | 24 | 9.8 | 2.2–28.7 (9.9) | 7 |
| 7 | Sirolimus | 14 | 1 | 9.1–11.5 (10.3) | 1 |
| 8 | Sirolimus | 1 | 2.3 | 3.2–16.5 (8.9) | 3 |
| 9 | Sirolimus | 1 | 1.4 | 7–19 (14.1) | 4; continuing treatment |
| 10 | Sirolimus | 1 | 1.2 | 8.7–15.3 (11.2) | 1 |
| Patients . | mTOR Inhibitor . | Age at Start, mo . | Maximal Dosage, mg/m2 · d . | Trough Level, μg/L (Mean) . | Duration of Treatment, mo . |
|---|---|---|---|---|---|
| 1 | Sirolimus | 28 | 2.1 | 3.1–11.4 (6.6) | 4 |
| 2 | Sirolimus | 40 | 5.9 | 3–11.8 (6.7) | 16; continuing treatment |
| 3 | Sirolimus | 27 | 3.7 | 4.4–23.5 (11.9) | 6 |
| 4 | Sirolimus | 7 | 3.2 | 4.4–4.8 (4.6) | 5 |
| 5 | Sirolimus | 57 | 3.5 | 1.6–10 (6.8) | 15; continuing treatment |
| 6 | Everolimus | 24 | 9.8 | 2.2–28.7 (9.9) | 7 |
| 7 | Sirolimus | 14 | 1 | 9.1–11.5 (10.3) | 1 |
| 8 | Sirolimus | 1 | 2.3 | 3.2–16.5 (8.9) | 3 |
| 9 | Sirolimus | 1 | 1.4 | 7–19 (14.1) | 4; continuing treatment |
| 10 | Sirolimus | 1 | 1.2 | 8.7–15.3 (11.2) | 1 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
